News | May 30, 2023
Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr
The company reported lifetime high EBIDTA of Rs. 250 crores
The company reported lifetime high EBIDTA of Rs. 250 crores
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
The product is expected to be launched in June 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
Product deliveries scheduled in Q3 of 2023
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The company has reported total income of Rs. 3276.35 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
